It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Due to their capacity to skew T cell responses towards Th1 oriented immunity, oligonucleotides containing unmethylated CpG motifs (CpG) have emerged as interesting adjuvants for vaccination. Whereas the signalling pathways in response to CpG mediated TLR9 activation have been extensively documented at the level of the individual cell, little is however known on the precise identity of the innate immune cells that govern T cell priming and polarisation to CpG adjuvanted protein antigens in vivo. In this study, we demonstrate that optimal induction of Th1 oriented immunity to CpG adjuvanted protein vaccines requires the coordinated actions of conventional DCs and of monocytes. Whilst conventional DCs were required for antigen presentation and initial T cell priming, monocytes constitute the main source of the Th1 polarising cytokine IL-12.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium; Department of Biochemistry, Ghent University, Ghent, Belgium; VIB Medical Biotechnology Center, Ghent University, Ghent, Belgium
2 Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium; VIB Medical Biotechnology Center, Ghent University, Ghent, Belgium
3 Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium
4 VIB Inflammation Research Center, Ghent University, Zwijnaarde, Belgium; Department of Respiratory Medicine, University Hospital Ghent, Ghent, Belgium
5 Department of Pharmaceutics, Ghent University, Ghent, Belgium